Top

Reactions Weekly

Published in:

01-05-2023 | Rhabdomyosarcoma | Case report

Cyclophosphamide/ifosfamide

Shrunken pore syndrome: 2 case reports

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Kooijmans ECM, et al. Shrunken pore syndrome in childhood cancer survivors treated with potentially nephrotoxic therapy. Scandinavian Journal of Clinical and Laboratory Investigation 82 : 541-548, No. 7, Jan 2022. Available from: URL: http://www.tandfonline.com/loi/iclb20

Title: Cyclophosphamide/ifosfamide
Shrunken pore syndrome: 2 case reports
Publication date: 01-05-2023
Publisher: Springer International Publishing
Keywords: Rhabdomyosarcoma
Leukemia
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-38389-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cyclophosphamide/ifosfamide

Shrunken pore syndrome: 2 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Prednisolone

Varenicline

Azathioprine/immune-globulin/prednisolone

Acetazolamide/antiglaucomas

Catequentinib/immune-checkpoint-protein-inhibitors

Antineoplastics